In:
Nature Communications, Springer Science and Business Media LLC, Vol. 12, No. 1 ( 2021-06-11)
Abstract:
Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma measurements of amyloid-β (Aβ)42/40, phospho-tau217 (P-tau217), and neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed for an average of 4.8 ± 1.7 years in the BioFINDER study. A combination of all three plasma biomarkers and basic demographics best predicted change in cognition (Pre-Alzheimer’s Clinical Composite; R 2 = 0.14, 95% CI [0.12–0.17]; P 〈 0.0001) and subsequent AD dementia (AUC = 0.82, 95% CI [0.77–0.91], P 〈 0.0001). In a simulated clinical trial, a screening algorithm combining all three plasma biomarkers would reduce the required sample size by 70% (95% CI [54–81]; P 〈 0.001) with cognition as trial endpoint, and by 63% (95% CI [53–70], P 〈 0.001) with subsequent AD dementia as trial endpoint. Plasma ATN biomarkers show usefulness in cognitively unimpaired populations and could make large clinical trials more feasible and cost-effective.
Type of Medium:
Online Resource
ISSN:
2041-1723
DOI:
10.1038/s41467-021-23746-0
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2553671-0